CD47 and anemia: As most anti-CD47 antibodies cause anemia due to phagocytosis of RBCs, Lemzoparlimab was generated to specifically target CD47 on malignant cells while not recognizing CD47 on RBCs, due to unique CD47 binding properties [206].